

BUPA INSURANCE COMPANY

Statutory Financial Statements
and Supplemental Schedules

December 31, 2023 and 2022

BUPA INSURANCE COMPANY

Table of Contents

	Page(s)
Independent Auditors' Report	1–3
Statutory Financial Statements:	
Statements of Admitted Assets, Liabilities, and Capital and Surplus	4
Statements of Income	5
Statements of Changes in Capital and Surplus	6
Statements of Cash Flow	7
Notes to Statutory Financial Statements	8–31
Supplemental Schedules	
Schedule I – Schedule of Investment Risks Interrogatories	32–33
Schedule II – Supplemental Summary Investment Schedule	34



Report of Independent Auditors

To the Board of Directors of BUPA Insurance Company,

Opinions

We have audited the accompanying statutory financial statements of BUPA Insurance Company (the “Company”), which comprise the statutory statements of admitted assets, liabilities, and capital and surplus as of December 31, 2023 and 2022, and the related statutory statements of income and of changes in capital and surplus, and of cash flows for the years then ended, including the related notes (collectively referred to as the “financial statements”).

Unmodified Opinion on Statutory Basis of Accounting

In our opinion, the accompanying financial statements present fairly, in all material respects, the admitted assets, liabilities, and capital and surplus of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in accordance with the accounting practices prescribed or permitted by the Florida Office of Insurance Regulation described in Note 1.

Adverse Opinion on U.S. Generally Accepted Accounting Principles

In our opinion, because of the significance of the matter discussed in the Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles section of our report, the accompanying financial statements do not present fairly, in accordance with accounting principles generally accepted in the United States of America, the financial position of the Company as of December 31, 2023 and 2022, or the results of its operations or its cash flows for the years then ended.

Basis for Opinions

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles

As described in Note 1 to the financial statements, the financial statements are prepared by the Company on the basis of the accounting practices prescribed or permitted by the Florida Office of Insurance Regulation, which is a basis of accounting other than accounting principles generally accepted in the United States of America.



The effects on the financial statements of the variances between the statutory basis of accounting described in Note 1 and accounting principles generally accepted in the United States of America, although not reasonably determinable, are presumed to be material.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the accounting practices prescribed or permitted by the Florida Office of Insurance Regulation. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the financial statements taken as a whole. The Schedule of Investment Risks Interrogatories and Supplemental Summary Investment Schedule (collectively referred to as the “supplemental schedules”) of the Company as of December 31, 2023 and for the year then ended are presented to comply with the National Association of Insurance Commissioners’ Annual Statement Instructions and Accounting Practices and Procedures Manual and for purposes of additional analysis and are not a required part of the financial statements. The supplemental schedules are the responsibility of management and were derived from and relate directly to the underlying accounting and other records used to prepare the financial statements. The supplemental schedules have been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental schedules are fairly stated, in all material respects, in relation to the financial statements taken as a whole.

PricewaterhouseCoopers LLP

Miami, Florida
May 31, 2024

BUPA INSURANCE COMPANY

Statutory Statements of Admitted Assets, Liabilities, and Capital and Surplus

December 31, 2023 and 2022

Admitted Assets	2023	2022
Bonds	\$ 85,251,006	91,648,950
Common stocks	—	24,185,536
Cash, cash equivalents, and short-term investments (including short-term bonds in the amount of \$42,096,458 and \$34,552,161 as of December 31, 2023 and 2022, respectively)	93,698,113	112,136,754
Contract loans	14,302	247,409
Total Cash, Cash Equivalents, and Invested Assets	178,963,421	228,218,649
Investment income due and accrued	2,925,216	1,851,044
Premiums due and unpaid	3,007,031	3,219,022
Other amounts receivable under reinsurance contracts	9,180,539	8,936,903
Federal and foreign tax receivable	2,354,635	32,871
Net Deferred Tax Asset	3,951,851	3,929,930
Receivable from subsidiaries and affiliates	7,967,331	8,718,276
Loan receivable from subsidiaries and affiliates	—	4,000,000
Other assets	15,617	6,387
Total Admitted Assets	\$ 208,365,641	258,913,082
Liabilities and Capital and Surplus		
Liabilities		
Claims unpaid (including life claims liability of \$0 at December 31, 2023 and \$19,470 at December 31, 2022)	\$ 25,295,132	26,847,340
Aggregate life policy reserves	639,793	912,551
Unearned health premium reserves	74,891,025	72,584,841
Premiums received in advance	2,494,989	2,421,855
General expenses due and accrued	3,696,963	3,821,130
Remittances and items not allocated	1,329,798	1,754,662
Federal and foreign income tax payable	1,044,921	61,908
Payable to subsidiaries and affiliates	2,308,228	526,260
Reinsurance commissions payable	6,057,936	3,848,455
Other liabilities and accruals	5,384	49,778
Total Liabilities	117,764,169	112,828,780
Capital and Surplus		
Common capital stock, par value of \$1.25. Authorized, 10,000,000 shares at December 31, 2023 and 2022; issued and outstanding, 8,414,181 at December 31, 2023 and 2022	10,517,727	10,517,727
Gross paid-in and contributed surplus	127,984,490	127,984,490
Unassigned surplus	(47,900,745)	7,582,085
Total Capital and Surplus	90,601,472	146,084,302
Total Liabilities and Capital and Surplus	\$ 208,365,641	258,913,082

The accompanying notes are an integral part of these statutory financial statements.

BUPA INSURANCE COMPANY
Statutory Statements of Income
Years ended December 31, 2023 and 2022

	<u>2023</u>	<u>2022</u>
Revenue:		
Net premium income	\$ 206,016,651	201,197,939
Change in unearned premium reserves and reserve for rate credits	(2,306,183)	(862,447)
Aggregate write-ins for other healthcare-related revenue	<u>905,684</u>	<u>1,009,235</u>
Total Revenue	<u>204,616,152</u>	<u>201,344,727</u>
Deductions:		
Hospital and medical benefits	59,736,516	72,099,534
Net insurance recoverable	74,268,136	69,709,188
Nonhealth claims	(21,964)	(398,647)
General administrative expenses (including commissions of \$56,765,062 and \$51,549,497 for the years ended December 31, 2023 and 2022, respectively)	<u>62,603,965</u>	<u>57,391,926</u>
Total Deductions	<u>196,586,653</u>	<u>198,802,001</u>
Net underwriting gain	8,029,499	2,542,726
Other income (expense):		
Gain on sale of subsidiary	3,168,226	—
Net realized capital losses	(693,299)	(10,036)
Net investment income	<u>8,964,434</u>	<u>3,418,947</u>
Net income from operations before income taxes	19,468,860	5,951,637
Federal and foreign income tax expense	<u>6,514,097</u>	<u>2,746,797</u>
Net income	<u>\$ 12,954,763</u>	<u>3,204,840</u>

The accompanying notes are an integral part of these statutory financial statements.

BUPA INSURANCE COMPANY

Statutory Statements of Changes in Capital and Surplus

Years ended December 31, 2023 and 2022

	Common capital stock	Gross paid-in and contributed surplus	Unassigned surplus (deficit)	Total
Balance – December 31, 2021	10,517,727	127,984,490	17,569,019	156,071,236
Change in net deferred tax asset	—	—	(4,178,090)	(4,178,090)
Change in nonadmitted assets	—	—	20,600,413	20,600,413
Change in net unrealized capital loss	—	—	10,085,903	10,085,903
Dividends paid to sole shareholder	—	—	(39,700,000)	(39,700,000)
Net income	—	—	3,204,840	3,204,840
Balance – December 31, 2022	10,517,727	127,984,490	7,582,085	146,084,302
Change in net deferred tax asset	—	—	21,921	21,921
Change in nonadmitted assets	—	—	29,115	29,115
Change in net unrealized capital loss	—	—	31,463,217	31,463,217
Dividends paid to sole shareholder	—	—	(99,951,846)	(99,951,846)
Net income	—	—	12,954,763	12,954,763
Balance – December 31, 2023	\$ 10,517,727	127,984,490	(47,900,745)	90,601,472

The accompanying notes are an integral part of these statutory financial statements.

BUPA INSURANCE COMPANY

Statutory Statements of Cash Flow

Years ended December 31, 2023 and 2022

	<u>2023</u>	<u>2022</u>
Cash flow from operations:		
Premiums collected, net of reinsurance	\$ 190,594,510	200,272,058
Net investment income	6,702,878	2,525,932
Other income	905,684	1,009,235
Benefits and loss-related payments	(119,011,192)	(155,876,981)
Commissions, expenses paid, and aggregate write-ins	(59,559,303)	(59,419,326)
Federal and foreign income taxes paid	<u>(7,852,848)</u>	<u>(2,254,996)</u>
Net cash provided by (used in) operations	<u>11,779,729</u>	<u>(13,744,078)</u>
Cash flow from investments:		
Proceeds from investments sold, matured, or repaid:		
Bonds	66,560,000	80,566,000
Common stocks	<u>58,816,979</u>	<u>—</u>
Total investment proceeds	<u>125,376,979</u>	<u>80,566,000</u>
Cost of investments acquired:		
Bonds	<u>(59,876,610)</u>	<u>(87,390,390)</u>
Total investments acquired	<u>(59,876,610)</u>	<u>(87,390,390)</u>
Net increase (decrease) in contract loans	<u>233,107</u>	<u>6,501</u>
Net cash provided by (used in) investments	<u>65,733,476</u>	<u>(6,817,889)</u>
Cash flow from financing and miscellaneous sources:		
Loan proceeds from subsidiaries and affiliates	4,000,000	29,700,000
Dividends paid to parent	<u>(99,951,846)</u>	<u>(39,700,000)</u>
Net cash used in financing and miscellaneous sources	<u>(95,951,846)</u>	<u>(10,000,000)</u>
Net change in cash, cash equivalents, and short-term investments	<u>(18,438,641)</u>	<u>(30,561,967)</u>
Cash, cash equivalents, and short-term investments, beginning of year	<u>112,136,754</u>	<u>142,698,721</u>
Cash, cash equivalents, and short-term investments, end of year	<u>\$ 93,698,113</u>	<u>112,136,754</u>

The accompanying notes are an integral part of these statutory financial statements.

(1) Organization and Significant Accounting Policies

(a) Organization

BUPA Insurance Company (the Company) is a health insurance company that files its annual report with the Florida Office of Insurance Regulation (Florida OIR). The Company was incorporated in 1973 and obtained a license to write specific coverage in the state of Florida in July 1973. The Company was acquired on September 9, 2005 by Grupo BUPA Sanitas (GBS), a subsidiary of the British United Provident Association (BUPA), a corporation domiciled in England. In October 2013, Bupa Investment Overseas Limited (BIOL), a subsidiary of BUPA, acquired a 33.19% interest in the Company. During 2014, BIOL increased its ownership interest to 59.28%. In December 2015, Bupa Investments Holdings Limited acquired all shares owned by both GBS and BIOL, becoming the Company's sole shareholder. During 2016, Bupa Investments Holdings Limited changed its name to Bupa Global Holdings Limited.

The Company provides accident and health and life insurance primarily to individuals in Latin America and the Caribbean.

(b) Basis of Presentation

The accompanying statutory financial statements of the Company have been prepared in conformity with accounting practices prescribed or permitted by the National Association of Insurance Commissioners' (NAIC) *Accounting Practices and Procedures Manual* and the Florida OIR, which is a comprehensive basis of accounting other than U.S. generally accepted accounting principles (GAAP). Prescribed statutory accounting practices include a variety of publications of the NAIC, as well as state laws, regulations, and general administrative rules. As of December 31, 2023 and 2022, the Company did not utilize any statutory accounting principles (SAP), which were not prescribed by insurance regulators.

SAP differ from GAAP in several respects, which cause differences in reported assets, liabilities, stockholder's equity (statutory capital and surplus), net income, and cash flows. The primary differences between SAP and GAAP include the following:

- Investments in bonds are carried at admitted value, which is based on NAIC designation. NAIC 1-2 are held at amortized cost, 3-6 are held at lesser of cost or fair value. Under GAAP, investments in bonds, other than those classified as held to maturity, are carried at fair value.
- Certain assets (principally, prepaid expenses, deposits, fixed assets, and receivables that are outstanding for more than 90 days from the due date) have been designated as nonadmitted assets and excluded from assets by a charge to statutory surplus. Under GAAP, such amounts are carried at cost less amortization or net realizable value.
- Deferred income taxes are recognized for both SAP and GAAP; however, the amount permitted to be recognized is generally more restrictive under SAP. Changes in deferred tax assets and liabilities are charged or credited directly to unassigned surplus under SAP. Under GAAP, these changes generally are included in net income. Admittance testing may result in a charge to surplus for nonadmitted portions of deferred tax assets.
- Policy acquisition costs are expensed as incurred, while under GAAP, these costs are deferred and recognized over either (i) the expected premium paying period or (ii) the estimated term of the contract. Under GAAP, assumed reinsurance commission allowances are also deferred as an offset to deferred policy acquisition costs and recognized in proportion to the related policy acquisition costs.

- Reserves are reported as liabilities, net of ceded reinsurance; under GAAP, reserves relating to business in which the Company is not legally relieved of its liability are reported gross with an offsetting reinsurance recoverable presented as an asset.
- The statutory statements of cash flow differ in certain respects from the presentation required by GAAP, including the presentation of the changes in cash and short-term investments instead of cash and cash equivalents. Savings accounts and certificates of deposit in banks or other financial institutions with maturities within one year or less from the acquisition date are classified as cash for financial statement purposes under SAP. Short-term investments include securities with maturities, at the time of acquisition, of 90 days or less. For statutory purposes, there is no reconciliation between net income and cash from operations.
- Statutory financial statements do not include reporting and display of comprehensive income as specified under GAAP.

(c) ***Use of Estimates***

The preparation of the statutory financial statements requires management to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the statutory financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include the carrying amount of unearned health premium reserves, premium deficiency reserves, liabilities for unpaid claims, doubtful accounts for receivables, and valuation allowances for deferred income taxes. Actual results could differ from those estimates, and such differences could be significant.

(d) ***Cash, Cash Equivalents, and Invested Assets***

In accordance with the requirements under SAP, bonds, certain preferred stock, and short-term investments are typically stated at amortized cost or the valuations promulgated by the NAIC. Investments in bonds not backed by other loans are generally carried at amortized cost, except where the NAIC designation indicates that a bond be carried at the fair value. Changes in prepayment assumptions are accounted for prospectively. Discount or premium on bonds is recorded for the difference between the purchase price and the principal amount, amortized using the effective-interest method. Interest revenue is recognized when earned. Realized gains or losses on sales of investments are determined on the basis of specific identified cost and recognized in net income. Short-term investments are stated at cost, which approximates fair value. For the purpose of the statutory statements of cash flow and the statutory statements of admitted assets, liabilities, and capital and surplus, short-term investments include investments that have a maturity of 90 days or less as of the date of acquisition and cash includes negotiable certificates of deposit that have a maturity date of one year or less at the date of acquisition.

If any unrealized losses are deemed other than temporary, such unrealized losses are recognized as realized losses in the Statutory Statements of Income. The Company has not recognized other-than-temporary losses on securities during 2023 or 2022.

Contract loans are stated at their unpaid principal balance, less an allowance for loan losses, if any. As of and for the years ended December 31, 2023 or 2022, the Company had no impaired contract loans.

The Company has provided deposits with a face value of \$99,126 and \$49,859 to Republic Bank (Anguilla) Limited as required by Anguilla Financial Services Commission, \$363,236 and \$356,895 to Arubabank as required by Centrale Bank Van Aruba, and \$250,000 and \$250,000 to BVI Financial Services Commission as required by British Virgin Islands Financial Services Commission as of December 31, 2023 and 2022, respectively. These amounts have been reported as components of cash, cash equivalents, and short-term investments in the accompanying statutory statements of admitted assets, liabilities, capital and surplus.

(e) **Investment in Mexican Subsidiary**

During 2003, the Company established Bupa Mexico, a 99.99% owned subsidiary, which was incorporated on July 31, 2003 in Mexico. The investment in this entity was recorded based on the underlying audited GAAP equity of Bupa Mexico adjusted to a statutory basis of accounting as required by Statements of Statutory Accounting Principles (SSAP) No. 97, *Investments in Subsidiary, Controlled, and Affiliated Entities, A Replacement of SSAP No. 88*. The value of this investment is \$0 and \$24,185,536 at December 31, 2023 and 2022, respectively, and is included in common stocks. On February 27, 2023 the Company sold its 99.9% interest in Bupa Mexico for \$ 58,999,922 to Bupa Global Holdings Limited (BGHL), an affiliate company.

(f) **Premium and Annuity Considerations Recognition and Acquisition Costs**

Accident and health insurance premiums are recognized as revenue ratably over the time period to which premiums relate. The liability for unearned premiums for accident and health contracts represents the unexpired portion of the premiums in force and is reported on the Statutory Statements of Admitted Assets, Liabilities, and Capital and Surplus as unearned health premium reserves.

Life and annuity premiums are recorded as income when due from policyholders under the terms of the insurance contract. Recognition of life premium income is consistent with the assumptions made in calculating the related policy reserve.

Costs of acquiring and renewing business are expensed as incurred.

(g) **Claims Unpaid**

The liability for unpaid accident and health contract claims, represents the amounts estimated to fund claims that have been reported but not settled and claims incurred but not reported. The liability for unpaid claims is estimated based on the Company's historical experience and other actuarial assumptions that consider the effects of current developments, anticipated trends, risk management programs, and renewal actions. Many factors affect actuarial calculations of claim liability including, but not limited to, current and anticipated incidence rates and economic and societal conditions. Management periodically performs a review of estimates and assumptions. If management determines assumptions need to be updated, any resulting adjustment to liabilities is reflected in the current year results. Given that insurance products contain inherent risks and uncertainties, the ultimate liability may be more or less than such estimates indicate.

(h) **Premium Deficiency Reserve**

The Company evaluates its health care contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, claims adjustment expenses and appropriate administrative costs will exceed anticipated future premiums on existing contracts, with consideration of investment income. For purposes of determining if a premium deficiency reserve exists, contracts are grouped in a manner consistent with the Company's method of acquiring, servicing and measuring the profitability of such contracts.

There were no premium deficiency reserves established as of December 31, 2023 and 2022

(i) **Income Taxes**

The Company determines income tax balances and related disclosures in accordance with SSAP No. 101, *Income Taxes, a Replacement of SSAP No. 10R and SSAP No. 10*.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to

be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in surplus in the period that includes the enactment date.

The Company classifies net interest expense related to tax matters and any applicable penalties as a component of general and administrative expense.

The admissibility of the Company's gross deferred tax assets is based on the provisions in paragraph 11 of SSAP No. 101.

(j) **Reinsurance**

The Company assumes health risks from affiliates. The Company has treaties with Bupa Guatemala Compañía de Seguros S.A. (Bupa Guatemala) and Bupa Dominicana S.A. (Bupa DR), companies under common ownership, which have both coinsurance and Excess of Loss (XOL) elements. Bupa Mexico, Bupa Panama S.A. (Bupa Panama) and Bupa Ecuador S.A., Compañía de Seguros y Reaseguros (Bupa Ecuador), Bupa Insurance Bolivia SA (Bupa Bolivia) only have XOL treaties with the Company. Bupa Insurance Limited (BINS) has a coinsurance treaty with the Company.

The Company has a reinsurance contract with Lloyds Syndicate #2001, managed by Amlin Underwriting Limited, covering 85% of both premiums and losses underwritten by Amlin.

BIC has a reinsurance contract with Compañía de Seguros Bolivar S. A. (Seguros Bolivar), a company incorporated in Colombia, where the Company reinsures 95% of both premiums and losses written by Seguros Bolivar.

Assumed reinsurance premiums, commissions, expense reimbursements, and reserves related to reinsured business are accounted for on the basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts.

All of these treaties have full transfer of risk for the amounts specified in the treaty. There are no additional premiums, allowances, or loss adjustments based on the portfolio experience that would limit the risk to the Company or return risk to the ceding companies. Based on these points, these contracts meet the requirements for reinsurance accounting.

(k) **Nonadmitted Assets**

Certain assets, such as work in progress, deferred tax assets, deposits, prepaid expenses, electronic data processing equipment, furniture and equipment, receivables 90 days past due, have been designated as nonadmitted assets by a charge to statutory surplus. Changes in these assets are presented as changes in unassigned surplus.

	<u>2023</u>	<u>2022</u>	<u>Increase in suplus for 2023</u>
Furniture and equipment	\$ 28,885	218,441	189,556
Work In Progress	155,303	—	(155,303)
Prepaid Insurance	5,138	—	(5,138)
Total non admitted assets	<u>\$ 189,326</u>	<u>218,441</u>	<u>29,115</u>

(l) ***Fair Value Measurement***

The fair value of financial instruments represents estimates of fair values at a specific point in time determined by the Company using available market information and appropriate valuation methodologies. These estimates are subjective in nature and involve uncertainties and significant judgment in the interpretation of current market data.

SSAP No. 100, *Fair Value Measurements*, specifies a fair value hierarchy based on whether the inputs to valuation techniques used to measure fair value are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's assumptions about market participants' assumptions based on the best information available in the circumstances. In accordance with SSAP No. 100, the fair value hierarchy prioritizes model inputs into three broad levels:

Level 1: Quoted prices for identical instruments in active markets that the Company has the ability to access;

Level 2: Quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments that are not in active markets, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3: Model-driven valuations in which one or more significant inputs or significant value drivers are unobservable.

As of December 31, 2023 or 2022, there were no significant financial assets and liabilities that are measured at fair value on a recurring basis. However, the Company discloses the fair value of bonds which are reported at amortized cost on the Statutory Statements of Admitted Assets, Liabilities, and Capital and Surplus as further discussed in note 2 and 3.

(m) ***Derivative Instruments and Hedging Activities***

Bupa Investments Limited (BIL) and Bupa Finance Limited (Bupa Finance), affiliated entities, enter into non deliverable forward contracts and foreign currency swaps on behalf of the Company in order to limit exposure to fluctuations in foreign currency exchange rates. These contracts were entered into in order to fix U.S. dollar (USD) amounts for a portion of the anticipated net cash flow related to policyholders' premiums and claims. The Company does not use derivative instruments for speculative purposes. The fair value of derivatives is estimated using available market information and appropriate valuation methodologies. The derivatives derive their value primarily based on changes in currency exchange.

All derivatives are recorded at fair value by BIL or Bupa Finance, and the changes in fair value are charged to the Company and included in earnings. The Company reported cash inflows of \$871,726 and \$464,630 related to realized gains on hedging transactions during 2023 and 2022, respectively. The unrealized gain of the outstanding contracts Bupa Finance held on behalf of the Company as of December 31, 2023 was \$208,638. The unrealized loss of the outstanding contracts BIL and Bupa Finance held on behalf of the Company as of December 31, 2022 was \$237,631. The notional principal amount related to these contracts was approximately \$6.5 million and \$4.9 million as of December 31, 2023 and 2022, respectively. The contracts are settled net; the unrealized gains or losses are recorded as an intercompany receivable (payable) with BIL or Bupa Finance, which has a corresponding asset (liability) with the respective banking institutions.

(2) Investments

The amortized cost, gross unrealized gains and losses, and fair value of investment securities as of December 31, 2023 are as follows:

	<u>Amortized cost</u>	<u>Gross unrealized gains</u>	<u>Gross unrealized losses</u>	<u>Fair value</u>
Bonds:				
U.S. Treasury securities and obligations of U.S. government agencies, states, and political subdivisions	\$ 10,561,083	44,824	(29,838)	10,576,069
Industrial and miscellaneous	<u>74,689,923</u>	<u>53,595</u>	<u>(67,076)</u>	<u>74,676,442</u>
Total bonds	<u>\$ 85,251,006</u>	<u>98,419</u>	<u>(96,914)</u>	<u>85,252,511</u>

The industrial and miscellaneous bonds comprise \$54.7 million of corporate bonds and two certificates of deposit issued by a financial institution for \$20.0 million.

The amortized cost, gross unrealized gains and losses, and fair value of investment securities as of December 31, 2022 are as follows:

	<u>Amortized cost</u>	<u>Gross unrealized gains</u>	<u>Gross unrealized losses</u>	<u>Fair value</u>
Bonds:				
U.S. Treasury securities and obligations of U.S. government agencies, states, and political subdivisions	\$ 788,532	1,308	(41,411)	748,429
Industrial and miscellaneous	<u>90,860,418</u>	<u>—</u>	<u>(1,033,057)</u>	<u>89,827,361</u>
Total bonds	<u>\$ 91,648,950</u>	<u>1,308</u>	<u>(1,074,468)</u>	<u>90,575,790</u>

The industrial and miscellaneous bonds comprise \$60.9 million of corporate bonds and three certificates of deposit issued by a financial institution for \$30.0 million.

The amortized cost, gross unrealized gains and losses, and fair value of short-term investments as of December 31, 2023 are as follows:

	<u>Amortized cost</u>	<u>Gross unrealized gains</u>	<u>Gross unrealized losses</u>	<u>Fair value</u>
Short-term bonds				
U.S. Treasury securities and obligations of U.S. government agencies, states, and political subdivisions	\$ 5,901,942	4,518	—	5,906,460
Industrial and miscellaneous	\$ 36,194,516	24,459	(5,018)	36,213,957
	<u>\$ 42,096,458</u>	<u>28,977</u>	<u>(5,018)</u>	<u>42,120,417</u>

The industrial and miscellaneous bonds comprise \$36.2 million of corporate bonds.

The amortized cost, gross unrealized gains and losses, and fair value of short-term investments as of December 31, 2022 are as follows:

	<u>Amortized cost</u>	<u>Gross unrealized gains</u>	<u>Gross unrealized losses</u>	<u>Fair value</u>
Short-term bonds				
Industrial and miscellaneous	\$ 34,552,161	—	(271,455)	34,280,706
Total short-term bonds	<u>\$ 34,552,161</u>	<u>—</u>	<u>(271,455)</u>	<u>34,280,706</u>

The industrial and miscellaneous bonds comprise \$34.6 million of corporate bonds

Gross unrealized holding gains and losses on investment securities for which other-than-temporary impairments have not been recognized and the fair values of those securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, as of December 31, 2023 and 2022, and were as follows:

2023					
Less Than 12 Months		12 Months or More		Total	
Fair Value	Gross unrealized losses	Fair Value	Gross unrealized losses	Fair Value	Gross unrealized losses
Bonds:					
U.S. Treasury securities and obligations of U.S. government agencies states, and political subdivisions					
		661,891	(29,839)	661,891	(29,839)
Industrial and miscellaneous	35,598,837	23,276,194	(20,130)	58,875,031	(67,075)
	<u>\$ 35,598,837</u>	<u>23,938,085</u>	<u>(49,969)</u>	<u>59,536,922</u>	<u>(96,914)</u>

2022					
Less Than 12 Months		12 Months or More		Total	
Fair Value	Gross unrealized losses	Fair Value	Gross unrealized losses	Fair Value	Gross unrealized losses
Bonds:					
U.S. Treasury securities and obligations of U.S. government agencies states, and political subdivisions					
		688,982	(41,411)	688,982	(41,411)
Industrial and miscellaneous	66,106,869	23,720,492	(230,495)	89,827,361	(1,033,057)
	<u>\$ 66,106,869</u>	<u>24,409,474</u>	<u>(271,906)</u>	<u>90,516,343</u>	<u>(1,074,468)</u>

At December 31, 2023 and 2022, all of the Company's securities are investment-grade fixed-income securities. Each of these investments is current on interest and principal payments. Unrealized losses were primarily due to interest rate fluctuations and market movements during the year and are not considered to be other-than-temporarily impaired as the Company has the intent and ability to hold these securities until they mature or recover in value.

Management considered several factors in determining that securities carried at an unrealized loss position were no other-than-temporarily impaired, including the nature of the investments, the severity and duration of the impairment, industry analyst reports and the volatility of the securities market price at the time the statutory financial statements were prepared. During 2023 and 2022, the Company recognized no other-than-temporary impairment losses on fixed-income securities.

The carrying values and fair value of bonds at December 31, by contractual maturity, are shown below:

	2023		2022	
	Amortized cost	Fair value	Amortized cost	Fair value
Due in 1 year or less	\$ 69,703,911	69,669,271	67,008,981	66,207,728
Due after 1 year through 5 years	15,443,300	15,478,757	24,639,969	24,368,063
Due after 5 years through 10 years	103,795	104,869	—	—
	<u>\$ 85,251,006</u>	<u>85,252,897</u>	<u>91,648,950</u>	<u>90,575,791</u>

There were sales of investment securities during 2023 and 2022 which resulted in a gross realized capital loss of \$693,299 and \$10,036, respectively. The credit quality of the bond portfolio at December 31 is identified in the table below. The quality ratings represent NAIC designations.

	2023		2022	
	Amortized cost	Percentage	Amortized cost	Percentage
NAIC 1 (highest quality)	\$ 85,251,006	100.0 %	91,648,950	100.0 %
	<u>\$ 85,251,006</u>	<u>100.0 %</u>	<u>91,648,950</u>	<u>100.0 %</u>

Bonds with ratings ranging from AAA/Aaa to BBB/Baa3, as assigned by a rating service such as Standard and Poor's Corporation or Moody's Investment Services, are generally regarded as investment-grade securities. Those securities issued or guaranteed by the U.S. government or an agency thereof are not rated but are considered to be investment-grade securities. The NAIC regards the U.S. government and agency securities and all A ratings as Class 1 (highest quality), BBB/Baa ratings as Class 2 (high quality), BB/Ba ratings as Class 3 (medium quality), B ratings as Class 4 (low quality), all C ratings as Class 5 (lower quality), and D ratings as Class 6 (in or near default).

Bonds include U.S. Treasury securities with a carrying value of \$301,432 and \$296,402 at December 31, 2023 and 2022, respectively, on deposit with the Florida OIR, as required by state insurance regulations. Bonds were also on deposit with the government of the U.S. Virgin Islands, with a carrying value of \$494,092 and \$492,130 at December 31, 2023 and 2022, respectively.

Net investment income for the years ended December 31, 2023 and 2022 comprises the following:

	<u>2023</u>	<u>2022</u>
Bonds	\$ 5,714,125	1,605,469
Related party loans	14,285	192,471
Commercial deposits	2,176,636	873,823
Derivative instruments	1,080,364	741,672
Other	<u>(3,744)</u>	<u>23,212</u>
Investment income	8,981,666	3,436,647
Investment expense	<u>17,232</u>	<u>17,700</u>
Net investment income	<u>\$ 8,964,434</u>	<u>3,418,947</u>

(3) **Fair Value Measurements**

The following table represents fair value of securities recorded or disclosed at fair value by SSAP No. 100 hierarchy levels as of December 31, 2023 and 2022:

	<u>2023</u>				
	<u>Admitted assets</u>	<u>Aggregate fair value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Financial assets:					
Bonds:					
U.S. Treasury securities and obligations of U.S. Government agencies, states, and political subdivisions	\$ 16,463,025	16,482,529	16,482,529	—	—
Industrial and miscellaneous	<u>110,884,438</u>	<u>110,890,785</u>	<u>—</u>	<u>110,890,785</u>	<u>—</u>
	<u>\$ 127,347,463</u>	<u>127,373,314</u>	<u>16,482,529</u>	<u>110,890,785</u>	<u>—</u>

2022

	Admitted assets	Aggregate fair value	Level 1	Level 2	Level 3
Financial assets:					
Bonds:					
U.S. Treasury securities and obligations of U.S. Government agencies, states, and political subdivisions	\$ 788,532	748,429	748,429	—	—
Industrial and miscellaneous	125,412,579	124,108,068	—	124,108,068	—
	\$ 126,201,111	124,856,497	748,429	124,108,068	—

The fair value estimates presented herein are based on quotations of national securities exchanges or pertinent information available to the Company as of December 31, 2023 and 2022. The estimated fair values of the financial instruments presented above were determined by the Company using market information available as of December 31, 2023 and 2022. Considerable judgment is required to interpret market data in developing the estimates of fair value for financial instruments for which there are no available market value quotations. The estimates presented are not necessarily indicative of the amounts the Company could have realized in a market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The carrying value of cash, cash equivalents, and short-term investments, contract loans, fees and other receivables, and accrued expenses approximates fair value due to short maturity or short duration of these instruments.

(4) Accident and Health Contract Claims

Activity in the liability for accident and health contract claims, net of reinsurance ended for the years ended December 31, 2023 and 2022 is summarized as follows:

	2023	2022
Claim reserves at January 1, net of amounts ceded	\$ 26,827,870	30,781,936
Incurred related to:		
Current year	138,140,699	141,760,493
Prior years	(4,136,047)	48,231
Total incurred	<u>134,004,652</u>	<u>141,808,724</u>
	2023	2022
Paid related to:		
Current year	\$ 114,195,253	117,704,668
Prior years	21,342,139	28,058,122
Total paid	<u>135,537,392</u>	<u>145,762,790</u>
Claim reserves at December 31, net of amounts ceded	<u>\$ 25,295,130</u>	<u>26,827,870</u>

As noted in the table above, the change in prior years' reserves was a decrease of \$4.1 million for 2023. Reserves remaining for prior year are now \$0.7 million as a result of re-estimation of unpaid claims and claim adjustment expenses mainly on health lines of insurance. The 2023 decrease was the result of having lower incurred claims in Q4 2022 than was originally anticipated, due to an absence of large claims. This resulted in a reduced ultimate risk cost than what had been expected based on trends up to the valuation date. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

The above table shows the components of changes in claim liabilities. Claim liabilities include claims in process as well as provisions for the estimate of incurred but not reported claims and provisions for disputed claim obligations. Such estimates are computed using actuarial principles and assumptions that consider, among other things, contractual requirements, historical utilization trends and payment patterns, benefit changes, medical inflation, seasonality, membership, and other relevant factors.

Because claim liabilities include various actuarially developed estimates, the Company's actual medical costs and claims expense may be more or less than the Company's previously developed estimates. As a result of changes in estimates, the incurred claims for prior period insured events during 2023 and 2022 were on par with anticipated cost per service and development. Management believes the amount of claims liabilities is reasonable and adequate to cover the Company's liability for unpaid claims and for claims incurred but not yet reported as of December 31, 2023, and 2022.

(5) Premium Deficiency

The Company evaluates its healthcare contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future paid claims, administrative expenses, and reserves will exceed existing reserves plus anticipated future premiums on existing contracts. Anticipated investment income and overhead expenses are also considered in the calculation of premium deficiencies. In 2023 and 2022, it was determined that no premium deficiency reserve was necessary due to the actual results being closer to the expected scenario than the moderately adverse scenarios that were the basis for the reserve in previous years.

(6) Federal Income Taxes

The current provisions for incurred taxes on earnings for the years ended December 31 are as follows:

	<u>2023</u>	<u>2022</u>
Federal	\$ 1,176,024	1,381,302
Foreign	<u>5,338,073</u>	<u>1,365,495</u>
Federal and foreign income tax provisions	<u>\$ 6,514,097</u>	<u>2,746,797</u>

A reconciliation of the federal income tax provision (other than capital gains) to the amount computed using the statutory federal income tax rate of 21% in 2023 and 2022 is as follows:

	<u>2023</u>	<u>2022</u>
Federal income taxes computed at the statutory rate	\$ 4,088,461	1,249,844
Change in nonadmitted assets	6,114	4,326,087
Change in valuation allowance	—	(246,931)
Foreign tax withholdings		1,078,741
GILTI	—	521,895
Other	2,623,060	(4,749)
	<u>6,717,635</u>	<u>6,924,887</u>
Federal and foreign income taxes provisions	\$ 6,717,635	6,924,887
Federal income tax provisions (benefit)	\$ 6,514,097	2,746,797
Change in net deferred income taxes	203,538	4,178,090
	<u>6,717,635</u>	<u>6,924,887</u>
Total statutory income taxes provisions	\$ 6,717,635	6,924,887

The components of net deferred tax assets and deferred tax liabilities recognized in the Company's statutory statements of admitted assets, liabilities, and capital and surplus at December 31, 2023 and 2022 are as follows:

	<u>2023</u>	<u>2022</u>
Total gross deferred tax assets	\$ 4,070,982	4,035,040
Adjusted gross deferred tax assets	4,070,982	4,035,040
Total deferred tax liabilities	<u>(119,131)</u>	<u>(105,110)</u>
Net deferred tax assets	3,951,851	3,929,930
Less: valuation allowance	<u>—</u>	<u>—</u>
Net admitted deferred tax assets	<u>\$ 3,951,851</u>	<u>3,929,930</u>
Increase (decrease) in admitted gross deferred tax assets	\$ 21,921	3,929,930

Deferred tax assets can only be admitted in an amount calculated under SSAP No. 101. The amount admitted is equal to the sum of (a) federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse by the end of the third subsequent calendar year plus, (b) the amount of adjusted deferred tax assets that are expected to be realized within three years of the balance sheet date after reduction by amounts that can be recovered through carrybacks and limited to 21% of adjusted statutory capital and surplus at December 31, 2023, and (c) the amount of adjusted gross deferred tax assets after application of (a) and (b) that can offset existing gross deferred tax liabilities.

The amount of admitted adjusted gross deferred tax assets admitted under each component of SSAP No. 101 as of December 31, 2023 and 2022 is as follows:

	<u>2023</u>	<u>2022</u>	<u>Change</u>
a. Federal income taxes paid in prior years recoverable through loss carryback	\$ 2,566,392	2,066,976	499,416
b. Adjusted gross deferred tax assets expected to be realized after application of threshold limitation	1,504,590	1,968,064	(463,474)
c. Adjusted gross deferred tax assets offset by deferred tax liabilities	<u>—</u>	<u>—</u>	<u>—</u>
	<u>\$ 4,070,982</u>	<u>4,035,040</u>	<u>35,942</u>

There are no temporary differences for which deferred tax liabilities are not recognized.

There are no tax planning strategies as of December 31, 2023 or 2022.

The amounts used in determination of admitted deferred tax assets in accordance with SSAP No. 101 are as follows:

Total adjusted capital (excluding DTA)	\$	86,649,620
Authorized control level		6,377,621
Risk-based capital percentage		1358.65%

The valuation allowance recorder for deferred tax assets was \$0 for December 31, 2023 and 2022. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment.

The net deferred tax asset at December 31, 2023 and 2022 and the change in deferred taxes comprise the following:

	December 31		Change
	2023	2022	
Total deferred tax assets net of valuation allowance	\$ 4,070,982	4,035,040	35,942
Total deferred tax liabilities	(119,131)	(105,110)	(14,021)
Net deferred tax asset	<u>\$ 3,951,851</u>	<u>3,929,930</u>	<u>21,921</u>

Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes and (b) operating loss and tax credit carryforwards. The tax effects of significant items comprising the Company's net deferred tax asset (all of which are operating in nature) as of December 31, 2023 and 2022 are as follows:

	2023	2022
Deferred tax assets:		
Unearned premium reserves	\$ 3,382,153	3,284,595
Accrued expenses and other	209,176	378,969
Other	479,653	371,476
Total deferred tax asset	4,070,982	4,035,040
Deferred tax liability:		
Property and equipment	<u>(119,131)</u>	<u>(105,110)</u>
Net deferred tax asset	<u>\$ 3,951,851</u>	<u>3,929,930</u>

The amount of federal income tax incurred that is available for recoupment in the event of future net losses for December 31, 2023 and 2022 is \$1,779,365 and \$787,026 respectively.

The Company files a federal and Florida income tax return. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2018. Potential state of Florida tax examinations for those years are generally restricted to results that are based on closed U.S. federal income tax examinations.

The Company is not subject to Repatriation Transition Tax (RTT) or the Alternative Minimum Tax nor does it have any recoverable AMT Credit Carryforward.

The Company has no tax loss contingencies for which it would be reasonably possible that the total liability will significantly increase within the twelve months of the reporting date.

The Inflation Reduction Act, which created a new corporate alternative minimum tax (CAMT) effective for calendar year taxpayers January 1, 2023, was enacted on August 16, 2022. Based upon projected adjusted financial statement income for 2023, the Company has determined that average "adjusted financial statement income" is below the thresholds for the 2023 tax year such that it does not expect to be required to perform the CAMT calculations, nor be liable for any CAMT.

(7) Reinsurance

The effects of reinsurance as of and for the year ended December 31, 2023 were as follows:

	<u>Accident and health contract/ life claims liability</u>	<u>Unearned health premium reserves</u>	<u>Premiums and annuity considerations written</u>	<u>Premiums and annuity considerations earned</u>	<u>Disability benefits and benefits under accident and health/ life contracts</u>
Direct	\$ 12,717,766	42,433,040	107,578,290	106,876,826	58,938,349
Assumed	12,577,366	32,457,985	98,440,965	96,836,246	75,044,338
Ceded	—	—	(2,605)	(2,605)	—
Total	<u>\$ 25,295,132</u>	<u>74,891,025</u>	<u>206,016,650</u>	<u>203,710,467</u>	<u>133,982,687</u>

The effects of reinsurance as of and for the year ended December 31, 2022 were as follows:

	Accident and health contract/ life claims liability	Unearned health premium reserves	Premiums and annuity considerations written	Premiums and annuity considerations earned	Disability benefits and benefits under accident and health/ life contracts
Direct	\$ 13,524,978	41,731,576	106,284,195	105,730,265	71,700,887
Assumed	13,322,362	30,853,265	94,918,426	94,609,909	70,101,684
Ceded	—	—	(4,682)	(4,682)	(392,496)
Total	<u>\$ 26,847,340</u>	<u>72,584,841</u>	<u>201,197,939</u>	<u>200,335,492</u>	<u>141,410,075</u>

The Company entered into a contract with Bupa Mexico effective October 1, 2021, where the company has an excess of loss coverage of 100% on claims above \$200,000. The Excess of loss premium paid to the Company is \$13.43 per member per month. On October 1, 2022, the Company entered into a new contract with Bupa Mexico where the company has an excess of loss coverage of 70% on claims above \$200,000. The Excess of loss premium paid to the Company is \$15 per member per month. The Company entered into a new contract with Bupa Mexico effective October 1, 2023, where the company has an excess of loss coverage of 30% on claims above \$200,000. The Excess of loss premium paid to the Company is \$21.08 per member per month.

The Company also has a reinsurance agreement with Bupa DR, where the Company assumes 45% of the premiums and claims with an excess of loss coverage of 100% on claims above \$30,000. Excess of loss premium paid to the Company by Bupa DR equals 0.5% of retained premiums. The Company pays a reinsurance commission of 37% on all of the premiums ceded, for reimbursement of expenses to Bupa DR.

The Company also has a reinsurance agreement with Bupa Guatemala, where the Company assumes 90.0% of the premiums and claims with an XOL coverage of 100% on claims above \$80,000. Reinsurance commission paid to Bupa Guatemala is 40% of ceded premiums. Excess of loss premium paid to the Company equals 0.5% of retained premiums.

The Company has an excess of loss reinsurance agreement with Bupa Panama, to cover any losses greater than \$100,000. Bupa Panama pays the Company \$20 per member per month.

Additionally, the Company entered into a reinsurance agreement with BINS, a company under common ownership. Under this agreement, BINS cedes 100% of claims and premiums net of commissions related to their Latin America portfolio to the Company. In exchange, the Company reimburses 100% of the operating expenses BINS incurs related to this portfolio.

Effective January 1, 2023 the Company has an excess of loss reinsurance agreement with Bupa Ecuador to cover any losses over \$40,000 for individual policies and \$200,000 for corporate policies. Bupa Ecuador pays the Company \$90 per member per month on individual policies and \$5.20 per member per month for corporate policies. On January 1, 2022 the Company has an excess of loss reinsurance agreement with Bupa Ecuador to cover any losses over \$40,000 for individual policies and \$200,000 for corporate policies. Bupa Ecuador pays the Company \$82 per member per month on individual policies and \$4.70 per member per month for corporate policies.

The Company has an excess of loss reinsurance agreement with Bupa Bolivia in 2023, to cover any losses greater than \$20,000. Bupa Bolivia pays the Company \$42.71 per member per month. The Company had an excess of loss reinsurance agreement with Bupa Bolivia in 2022, to cover any losses greater than \$150,000. Bupa Bolivia pays the Company \$5,000 per year, within 60 days following year-end.

The Company has a reinsurance agreement with Lloyd's Syndicate #2001, managed by Amlin Underwriting Limited (Amlin), where the Company assumes 85% of premiums, net of any commissions and fees paid by Amlin to Bupa Worldwide Corporation and to U.S.A. Medical Services Corporation, companies related through common ownership. The Company is liable for 85% of all losses. BIC pays a reinsurance commission of 4% on the net reinsurance premium.

The Company has a reinsurance agreement with Compañía de Seguros Bolivar S. A. (Seguros Bolivar), a company incorporated in Colombia, where the Company assumes 95% of premiums net of applicable tax and commissions. Under Colombian law, Seguros Bolivar must retain 20% of the ceded premium and may release it after a calendar year. Seguros Bolivar will recognize an interest rate of 1.5% over such deposit, subject to withholding tax of 15%. The Company will reimburse Seguros Bolivar 95% of all claims paid. Reinsurance commission paid by BIC on the joint venture agreement is 20% of the reinsurance premiums for individual business and 18% for Group business and 29% for the legacy agreement.

The Company has a reinsurance agreement with Alltrust Insurance Company a company incorporated in China, where the Company assumes 10% of premiums. The Company will reimburse Alltrust Insurance Company 10% of all claims paid. Reinsurance commission paid by BIC is 15% of the reinsurance premiums.

Effective March 1, 2023, the Company entered into a new reinsurance contract with Mapfre Peru Compañía de Seguros y Reaseguros S.A (Mapfre), a company incorporated in Peru, with both and quota share and excess of loss components. The quota shares has the Company assuming 70% of the risk, with a 30% commission. The excess of loss will cover claims over \$150,000 and the premium is 2.8% of the 30% of the risk retained by Mapfre.

(8) Retirement Plan

The Company has a voluntary defined-contribution 401(k) profit-sharing plan (the Plan) in which eligible employees may participate. Employees are eligible to participate in the Plan upon the attainment of age 21 and completion of six months of service. Participants may elect to contribute up to \$22,500 of their annual compensation, not to exceed amounts prescribed by statutory guidelines, for the year ended December 31, 2023 and \$20,500 for the year ended December 31, 2022. The Company's matching contribution is 7% of employee's salary. Contributions to the Plan were \$24,895 and \$40,615 for the years ended December 31, 2023 and 2022, respectively.

(9) Managing General Agent

Bupa Worldwide Corporation (BW) has the exclusive contract to serve as managing general agent to the Company. The Company is located at 18001 Old Cutler Road, Palmetto Bay, FL, 33157, with FEIN# 59-2729914. BW provides marketing, agent administration, and policy administration services. The type of authority granted by the Florida OIR is B (Binding Authority) and P (Premium Collection). Approximately \$107.6 million and \$106.3 million of direct premiums were written through BW, including accident and health, ordinary life, and term life, for the year ended December 31, 2023 and 2022, respectively. The Company paid BW commissions of \$15,751,656 and \$13,679,548 for these services in 2023 and 2022, respectively. Per the terms of the managing general agent agreement, BW must be paid for the administrative fee due on a monthly basis. BW may offset any existing or future indebtedness of the Company to BW against any future claims for compensation payable to the Company by BW.

(10) Transactions with Related Parties

The Company has a third-party administration agreement with U.S.A. Medical Services Corporation (USAMS) and U.S.A. Medical Services DR (USADR) under which USAMS and USADR provide claims administration and medical referral services to the Company for a fee. The Company paid USAMS and USADR fees for these services of \$3,555,570 and \$3,610,125 in 2023 and 2022, respectively. These fees are recorded as hospital and medical benefits expense in the accompanying Statutory Statements of Income.

In 2016, the Company provided an unsecured loan to Bupa Investments Overseas Limited (BIOL) in the amount of \$29,700,000. The full amount of the loan was paid off on June 15, 2022.

Effective January 1, 2022, an intercompany expense allocation agreement was placed in effect among the Company, Bupa Investment Corporation, Inc., Bupa Worldwide Corporation, Bupa U.S. Holdings, Inc., U.S.A. Medical Services Corporation (USAMS), Bupa Insurance Limited, Bupa Insurance Services, Ltd, Bupa Denmark Services A/S, Bupa Dominicana, S.A., Bupa Insurance (Bolivia) S.A., Bupa Panama, S.A., Bupa Guatemala Compania De Seguros, S.A., Bupa Mexico Compania De Seguros S.A. DE C.V., Bupa Servicios de Evaluacion Medica, s. de R.L. de C.V., Bupa Ecuador S.A., Compania De Seguros Y Reaseguros, Care Plus Medicina Asistencial Ltda., Amedex Insurance Company (Bermuda) LTD, Integramedica Peru S.A.C, MediPeru S.A., Anglolib S.A., Amedex Services LTD. and Bupa Servicios Panama, S.A. The agreement states that each paying party is authorized to pay for direct costs on behalf of one or more of the other party or parties in exchange for reimbursement for such payments from the respective purchasing party or parties. Payments shall be in the exact amount, including all applicable incurred taxes. The total payable included within payable to subsidiaries and affiliates at December 31, 2023 was \$220,728. The total receivable included within receivable from subsidiaries and affiliates was \$12,941 at December 31, 2022.

In November 2013, the Company signed sublease agreements with BW and USAMS to allocate the cost of a 10-year lease in an office building located in Palmetto Bay, Florida. The Company charges BW and USAMS for the portion of the space used. Total rental income is included as an offset to general administrative expenses and amounted to \$2,013,865 in 2023 and \$2,009,943 in 2022.

On February 13, 2013, the Company provided an unsecured loan to USAMS in the amount of \$4,000,000, maturing on February 23, 2023. The loan bears interest, payable quarterly in arrears on the last business day of each calendar quarter, at a 3% rate per annum. The full amount of the loan was paid off on February 13, 2023. Interest income for the years ended December 31, 2023 and 2022 amounted to \$14,285 and \$120,300 respectively.

(11) **Regulatory Matters**

The Company is subject to regulation by the Florida OIR. Florida insurance regulations require the Company to maintain not less than the greater of unimpaired paid-in surplus of \$40.0 million, or 4%, of total liabilities, plus 6% of liabilities relative to health insurance. The Company is restricted by Florida insurance statutes as to the amount of dividends which can be paid. Dividends can only be paid out of available and accumulated surplus funds, which are derived from realized net operating profits and net realized capital gains. The maximum amount of dividend paid must be the lower of 10% of capital and surplus or 100% of the net operating profits and realized net capital gains derived during the immediate preceding calendar year. During 2023 two dividends were declared, in the amount of \$89,951,846 paid on April 28, 2023 and \$10,000,00 paid on December 15, 2023. During 2022 two dividends were declared, in the amount of \$10,000,00 paid on April 19, 2022 and \$29,700,000 paid on June 15, 2022. The Company cannot distribute dividends in 2024 without prior approval from the Florida OIR.

The Company is required to comply with NAIC risk-based capital (RBC) requirements. RBC is a method of measuring the amount of capital appropriate for an insurance company to support its overall business operations in light of its size and risk profile. NAIC RBC standards are used by regulators to determine appropriate regulatory actions relating to insurers who show signs of weak or deteriorating conditions. As of December 31, 2023 and 2022, based on calculations using appropriate NAIC formulas, the Company's total adjusted capital was in excess of ratios that would require any form of regulatory action.

(12) **Concentration of Premiums**

The distribution by country of accident and health premiums written by the Company is as follows for the years ended December 31, 2023 and 2022:

	<u>2023</u>	<u>2022</u>
Mexico	15 %	15 %
Guatemala	13	13
Colombia	10	10
Venezuela	8	8
Ecuador	7	7
Others	47	47
Total	<u>100 %</u>	<u>100 %</u>

(13) **Commitments and Contingencies**

The Company is a party to various claims, legal actions, and complaints arising in the ordinary course of business. While any proceeding or litigation has an element of uncertainty, management believes that the disposition of these matters will not have a material impact on the statutory financial position, liquidity, or results of operations of the Company.

(14) **Leases**

In November 2013, the Company signed a lease agreement for a 10-year lease in an office building located in Palmetto Bay, Florida.

Rental expense for these operating leases was \$1,832,860 in 2023 and \$1,780,779 in 2022.

Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2023 are:

	<u>Minimum lease payments</u>
Year ending December 31:	
2024	<u>539,977</u>
Total minimum lease payments	<u>\$ 539,977</u>

In November 2013, the Company signed sublease agreements with BW and USAMS to allocate the cost of a 10-year lease in an office building located in Palmetto Bay, Florida, as stated in note 10 above.

Future minimum sublease receipts in the future under these leases as of December 31, 2023 are:

	BW minimum sublease receipts	USAMS minimum sublease receipts
	<u> </u>	<u> </u>
Year ending December 31: 2024	<u>408,763</u>	<u>100,976</u>
Total minimum sublease receipts	<u>\$ 408,763</u>	<u>100,976</u>

(15) Subsequent Events

Effective May 1, 2024 the Company extended the existing lease until August 31, 2029, as well reducing the office space to 17,817 rentable square feet. The Company has evaluated subsequent events through May 31, 2024, the date at which the financial statements were available to be issued. The Company has determined that there are no other items to disclose.

SUPPLEMENTAL SCHEDULES

BUPA INSURANCE COMPANY

Schedule of Investment Risks Interrogatories

December 31, 2023

1. The Company's total admitted assets as reported in the statutory statement of admitted assets, liabilities, and capital and surplus at December 31, 2023 were: \$ 208,365,641

2. The largest exposures to a single issue/borrower/investment, by investment category, excluding: (i) U.S. government, U.S. government agency securities, and those U.S. government money market funds listed in the Appendix to the *SVO Purposes and Procedures Manual* as exempt, (ii) property occupied by the Company, and (iii) policy loans at December 31, 2021 are as follows:

Issuer	Description of exposure	Amount	Percentage of total admitted assets
Standard Chartered Bank	Cash/Bonds	\$ 40,000,000	19
MUFG Bank Ltd.	Cash/Bonds	20,000,000	10 %
United States Treasury	Bonds	16,463,025	8
Toronto-Dominion Bank	Bonds	15,002,863	7
Wells Fargo	Cash	10,889,292	5
Toyota Motor Credit Corp	Bonds	10,293,344	5
Merck & Co Inc.	Bonds	9,891,158	5
Royal Bank of Canada	Bonds	9,703,977	5
John Deere Capital Corp	Bonds	9,362,044	4
Pfizer Inc.	Bonds	7,467,617	4

3. The amount and percentage of the Company's total admitted assets held in bonds by NAIC rating are as follows:

Bonds	Amount	Percentage
NAIC-1	\$ 127,347,483	61 %

4. The largest exposures to foreign investments are as follows:

Issuer	Investment category	Amount	Percentage of total admitted assets
		\$ —	— %

5. Aggregate foreign investment exposure by NAIC sovereign designation:

NAIC Designation	Amount	Percentage
Countries designated NAIC – 1	\$ —	— %
Countries designated NAIC – 2	—	— %
Countries designated NAIC – 3 or below	—	— %

6. The largest foreign investment by country, categorized by country's NAIC sovereign designation:

Country Designated NAIC	Amount	Percentage
	\$ —	— %

7. N/A

8. N/A

9. N/A

10. N/A

11. There were no assets held in Canadian investments that exceeded 2.5% of total admitted assets.

12. There were no assets held in investments with contractual sales restrictions.

BUPA INSURANCE COMPANY

Schedule of Investment Risks Interrogatories

December 31, 2023

13. The largest exposure to equity interests is as follows:

Issuer	Amount	Percentage of total admitted assets
	\$ —	— %

14. There were no privately placed equities.

15. There were no assets held in general partnership interests.

16. There were no assets held in mortgage loans that exceeded 2.5% of total admitted assets.

17. N/A

18. There were no assets held in real estate.

19. There were no admitted assets held in mezzanine real estate loans.

20. There were no admitted assets subject to securities lending, repurchase, reserve repurchase, dollar repurchase, or dollar reserve repurchase.

21. There were no warrants.

22. There was no exposure for collars, swaps, or forwards.

23. There was no exposure for future contracts.

24. There were no write-ins for invested assets category included on the summary investment schedule in the annual statement.

Refer to Section 2 of Appendix A-001 to the NAIC *Accounting Practices and Procedures Manual*.

BUPA INSURANCE COMPANY

Supplemental Summary Investment Schedule

December 31, 2023

	Gross investment holdings	Percentage	Admitted assets	Percentage
Bonds:				
U.S. Treasury securities	\$ 10,561,083	5.9 %	\$ 10,561,083	5.9 %
U.S. government agency and corporate obligations (excluding mortgage-backed securities (MBS))	—	— %	—	— %
Securities issued by states, territories, and possessions and political subdivisions in the United States:				
States, territories, and possessions general obligations	—	— %	—	— %
Political subdivision of states, territories, and possessions and political subdivisions general obligations	—	— %	—	— %
Collateralized mortgage obligation and real estate mortgage investment conduits:				
Privately issued and collateralized by MBS issued or guaranteed by GNMA, FNMA, or FHLMC	—	— %	—	— %
Other debt and other fixed-income securities (excluding short term)	54,689,923	30.6 %	54,689,923	30.6 %
Unaffiliated certificate of deposits	20,000,000	11.2 %	20,000,000	11.2 %
Equity interests:				
Investment in mutual funds	—	— %	—	— %
Preferred stocks:				
Unaffiliated	—	— %	—	— %
Publicly traded equity securities (excluding preferred stocks):				
Unaffiliated	—	— %	—	— %
Other equity securities:				
Affiliated	—	— %	—	— %
Contract loans	14,302	0.01 %	14,302	0.01 %
Receivables for securities	—	— %	—	— %
Cash, cash equivalents, and short-term investments	93,698,113	52.5 %	93,698,113	52.5 %
Other invested assets	—	— %	—	— %
Total invested assets	<u>\$ 178,963,421</u>	<u>100 %</u>	<u>\$ 178,963,421</u>	<u>100 %</u>